Skip to Content

Eptinezumab Approval Status

FDA Approved: No
Generic name: eptinezumab
Company: Alder BioPharmaceuticals, Inc.
Treatment for: Migraine Prevention

Eptinezumab is an investigational monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP) in development for migraine prevention.

Development Status and FDA Approval Process for eptinezumab

DateArticle
Jun 27, 2017Alder BioPharmaceuticals Announces Positive Eptinezumab Phase 3 Results for Prevention of Frequent Episodic Migraine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide